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ABSTRACT 
A method for conditional control of orthogonal sequential Cu-catalyzed azide alkyne cycloaddition 
(CuAAC) reactions is reported. The inherent reactivity of an aromatic ynamine is controlled by a silyl 
protecting group that allows the selective CuAAC reaction of less reactive alkynes. Alternatively, the 
same protected ynamine undergoes selective CuAAC reaction via silyl deprotection in situ to give the 
ynamine click products. This allows complete orthogonal control of dialkyne systems  and provides a 
unifying strategy for chemoselective CuAAC ligations in multi-alkyne/azide systems. 
 
The Cu-catalyzed azide-alkyne cycloaddition (CuAAC) or ÔclickÕ reaction has become a method of 
choice for a variety of broadly different applications throughout both chemistry and biology.1,2 This 
popularity arises from the reliable synthesis of 1,4-substituted triazoles using readily available 
terminal alkyne and azides. The predictability of this reaction has led to broad utility within materials 
chemistry,3 chemical biology,4 and combinatorial chemistry.5 A powerful extension of the CuAAC 
reaction uses multi-alkyne/azide systems, where several click events are performed sequentially.6 This 
allows the generation of, for example, two unique triazole products using two alkynes and two azides, 
or multi-functional products from the union of a diyne with two azide partners. The success of this 
strategy relies upon chemoselective control of the alkyne and azide coupling partners.  
 
Azide chemoselectivity is typically achieved using chelate-direction, where a Cu-chelating site 
increases the reactivity of an azide in close proximity.7 Alkyne chemoselectivity has been the primary 
focus in this area, with two main approaches. (1) Alkyne deactivation: Protected alkynes allow 
orthogonal control (Scheme 1a).8 While this has led to a number of elegant reports of sequential click 
reactions, the order of reactivity is typically determined at inception with little opportunity for 
diversification. (2) Alkyne activation: several highly reactive alkynes have been developed to establish 
a reactivity gradient.9 However, truly orthogonal reactivity has only been demonstrated in strain-
promoted alkyne-azide cycloaddition (SPAAC)/CuAAC bifunctional systems where the high 
azidophilicity of cyclic alkynes allows selectivity over terminal alkynes in the absence of a Cu catalyst 
(Scheme 1b).10 Transient protection of cyclooctynes offers sequential control;11 however, the 
formation of regioisomeric products from SPAAC can pose problems for downstream applications due 
to potential differences in regioisomer pharmacology.12 
  
At present, sequential CuAAC methodologies are uni-directional, i.e., there is a pre-designed 
deactivation of one alkyne and this reactivity gradient cannot be completely overturned. In addition, 
few methods are available to perform sequential CuAAC reactions exploiting chemoselective control 
of both alkyne and azide reagents.13 Here we describe a conditional strategy for complete orthogonal 
control over CuAAC reactions in multi-alkyne/azide systems using a single aromatic ynamine 
construct (Scheme 1c). 
 
c) This work: Orthogonal CuAAC reactions using single aromatic ynamine construct
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Scheme 1. (a) Alkyne selectivity using protecting groups. (b) Control using CuAAC vs. SPAAC. (c) 
Orthogonal alkyne/ynamine selectivity using a conditional strategy.  
 
Aromatic ynamines display enhanced reactivity over a series of more conventional alkynes due to a 
shift in the rate-determining step (RDS) of this class of reagent.14 The enhanced reactivity of an 
ynamine, (e.g., 1) vs. a standard terminal alkyne (e.g., 2a) enables chemoselective triazole formation 
under CuAAC conditions (Scheme 2).15 
 
Scheme 2. Design plan.  
 
The reciprocal reaction, i.e., chemoselective reaction at the less reactive alkyne, is rather more difficult 
based on this kinetic profile. This is another example of uni-directional CuAAC. However, we 
reasoned that conditional orthogonal control could be delivered using a simple protecting group 
strategy. Specifically, TIPS protection of 1 to give 4 would block the natural reactivity of 1 and 
thereby allow the reaction of a less reactive alkyne (e.g., 2a). This would effectively reverse the 
reactivity trend. To restore the normal reactivity, a rapid in situ silyl deprotection using a fluoride 
source would deliver 1 that would then react preferentially (Scheme 2). This approach would deliver a 
conditional bi-directional strategy for sequential control of two CuAAC reactions. 
 
We began our investigation through the reaction of 4, benzyl azide (BnN3, 6a), and a representative 
terminal alkyne (2a) under a range of standard reaction conditions (Table 1). First, chemoselectivity 
















































Cu cat., FÐ, R N3
delivering triazole product 5a in quantitative yield without any degradation of 4 (entry 1). We then 
sought to restore ynamine chemoselectivity though addition of TBAF as a source of FÐ. Initial 
experiments using standard Cu(I) ligands (1-(trans-2-hydroxycyclohexyl)-4-(N,N-
dimethylaminomethyl)-1,2,3-triazole (AMTC), tris(3-hydroxypropyltriazolylmethyl)amine (THPTA)) 
and TBAF or polymer-supported fluoride were unsuccessful in any solvent mixture, delivering 
mixtures of products (entries 2-6). Removal of Cu-ligating additives and variation of the solvent 
(entries 7-10) led quickly to a system that delivered complete chemoselectivity for 3a (entry 10). 
Solvent choice was an important factor for chemoselective control. Standard CuAAC solvent mixtures 
of DMSO/H2O conditions operated well for CuAAC reaction of the alkyl alkyne 2a whereas DMSO 
and DMSO/H2O mixtures were not effective for selectivity at the ynamine 4. Ynamine selectivity was 
optimum using MeCN as the reaction medium. This difference in medium may be attributable to the 
requirement for sodium ascorbate (NaAsc) as an additive to promote reaction of 2a and the improved 
solubility of NaAsc in H2O. NaAsc was not necessary for reaction of 4. That 4 does not need NaAsc as 
a promoter may be attributable to reduction of Cu(II) to Cu(I) via Glaser coupling.2 Since complete 
chemoselectivity for reaction at the ynamine using the in situ deprotection method (entry10), this 
suggests that the silyl deprotection is sufficiently rapid to have little consequence of the CuAAC 
process, i.e., the overall rate of silyl deprotection and CuAAC of 4 is less than the CuAAC rate of 2a. 
 
 
Table 1. Reaction development.a 
 
entry reaction conditions 3a:5a (%)b 
1 NaAsc, AMTC, DMSO/H2O (1:1) 0:100 
2 NaAsc, AMTC, TBAF, MeOH/H2O (1:1) 47:53 



























4 NaAsc, AMTC, PS Fluoride, DMSO/H2O 15:85 
5 NaAsc, THPTA, TBAF, DMSO/H2O (1:1) 43:57 
6 NaAsc, THPTA, PS Fluoride, DMSO/H2O (1:1) 63:37 
7 PS Fluoride, DMSO 35:65 
8 TBAF, DMSO 47:53 
9 TBAF, MeOH 16:84 
10 TBAF, MeCN 100:0 
a 
2a (1 equiv), 4 (1 equiv), 6a (1 equiv), Cu(OAc)2 (5 mol %), NaAsc/AMTC/THPTA (10 mol %), fluoride source (1.1 
equiv), solvent (0.03 M), r.t., 16 h. b Determined by HPLC analysis using an internal standard. PS = polymer supported. 
 
With optimized conditions for orthogonal reactivity in this benchmark system established, we 
progressed to look at the generality of the process. The scope and orthogonality of the developed 
conditions A (ynamine-selective) and B (alkyne-selective) was first assessed using a series of azide 
components (Scheme 3). Both sets of conditions proved to be robust, selectively delivering the 
expected products in high yield regardless of steric or electronic nature of the azide. In addition bio-
relevant azides were well tolerated, such as the fluorophores 6g-i, and biotinyl azide 6j. 
 
 Scheme 3. Selective orthogonal CuAAC reactions of 4 and 2a using a variety of azides using 
conditions A or B. Isolated yields. a Using MeOH/H2O (1:1) as solvent. 
b Using MeOH as solvent. 
 
The orthogonality of the approach was further probed using a series of different alkyne components 
vs. 4 (Scheme 4).  
 






































































Conditions A: Cu(OAc)2 (5 mol %), NaAsc (10 mol %), AMTC (10 mol %), DMSO/H2O (1:1), r.t.















































Conditions A: Cu(OAc)2 (5 mol %), NaAsc (10 mol %), AMTC (10 mol %), DMSO/H2O (1:1), r.t.












































 Activated alkynes 2b and 2c display enhanced reactivity in CuAAC reactions over propargyl 
substrates (e.g., 2d) as well as aromatic (2e) and aliphatic alkynes (2f).9 Under alkyne-selective 
conditions (Conditions A), full conversion to the expected triazoles 7a-f was observed, with isolated 
yields >85%. When changing to the ynamine-selective conditions (Conditions B), chemoselectivity 
remained in favor of the ynamine, although the level of selectivity was lower for more reactive 
alkynes (2b, 2c) as could be anticipated based on previous studies.14  
 
Orthogonal control was further explored first by use of the diyne 8 (Scheme 5). Preparation of the 
regioisomeric bis-triazole products 11a and 11b could be achieved either by reacting at the terminal 
alkyne then the ynamine (Conditions A then B) or by reaction at the ynamine followed by the terminal 
alkyne (Conditions B then A). This was not conditional on strategic use of a particular azide: The 
overall yield of 11a and 11b using both approaches was >90%, further demonstrating the 



















































Conditions A Conditions B
(6a, 1 equiv)BnN3
(6a, 1 equiv)BnN3











































Conditions A Conditions B
(6k, 1 equiv)c-HexN3
(6k, 1 equiv)c-HexN3
Conditions B Conditions A
(6a, 1 equiv)BnN3
98%
Scheme 5. Orthogonal CuAAC reactions on a diyne scaffold. 8. Isolated yields.  
Lastly, we investigated the ability to simultaneously control both chemoselectivity at the alkyne as 
well as the azide component through exploitation of chelate-assistance to afford control over the azide 
(Scheme 6).7 Under alkyne-selective conditions (Conditions A), the multicomponent reaction of 2e, 4, 
6a, and 6f delivers product pair 3a and 12 via first CuAAC reaction of 2e with the more reactive azide 
6f.7a Addition of TBAF liberates the reactive ynamine allowing the second CuAAC reaction with 
azide 6a to take place. Alternatively, the orthogonal product pair, 3f and 7e, is generated using the 
ynamine-selective protocol (Conditions B) to promote the reaction of ynamine with 6f and the alkyne 
with 6a. 
 
Scheme 6. Reactivity pairing of sequential CuAAC reactions. Isolated yields. 
 
CONCLUSIONS 
In summary, we have shown that orthogonal control of alkyne reactivity in CuAAC reactions can be 
controlled by the strategic use of a silyl protecting group. This allows the development of the first 
conditional orthogonal strategy for alkynes in CuAAC reactions, and displays excellent 
chemoselectivity profiles in single competition experiments as well as within multi-component 
reactions. We envisage the flexibility of this approach will provide new opportunities for 













































General. All reagents and solvents were obtained from commercial suppliers and were used without 
further purification unless otherwise stated. Purification was carried out according to standard 
laboratory methods. Intermediates 4,16 2a,17,18 6b,19 6d,20 6e,21 6g,22 6h,23 6i,24 6j,25 2b,16 2c,26 2d,27 8,15 
and AMTC28 were prepared according to literature procedures. Dry solvents for reactions were either 
obtained from a PureSolv SPS-400-5 solvent purification system, transferred to and stored in a 
septum-sealed oven-dried flask over previously activated 4  molecular sieves and purged with and 
stored under nitrogen, or either used as obtained from suppliers without further purification. Reactions 
were carried out using conventional glassware (preparation of intermediates). Purging refers to a 
vacuum/nitrogen-refilling procedure. Room temperature was generally 18 ¡C. Reactions were carried 
out at elevated temperatures using a temperature-regulated hotplate/stirrer. 
Purification. Thin layer chromatography was carried out using Merck silica plates coated with 
fluorescent indicator UV254. These were analyzed under 254 nm UV light or developed using 
potassium permanganate solution. Normal phase flash chromatography was carried out using 
ZEOprep 60 HYD 40-63 µm silica gel.  
Analysis. Fourier Transformed Infra-Red (FTIR) spectra were obtained on a Shimadzu IRAffinity-1 
machine. 1H and 13C NMR spectra were obtained on either a Bruker AV 400 at 400 MHz and 100 
MHz, respectively, or Bruker DRX 500 at 500 MHz and 126 MHz, respectively. Chemical shifts are 
reported in ppm and coupling constants are reported in Hz with CDCl3 referenced at 7.26 ppm (1H) 
and 77.0 ppm (13C), DMSO-d6 referenced at 2.50 ppm (1H) and 39.5 ppm (13C), and MeOD 
referenced at 4.78 ppm (1H) and 49.2 ppm (13C). High resolution mass spectroscopy was recorded on a 
Bruker maXis Impact TOF mass spectrometer, equipped with an ESI interface, over a mass range of 
50 Ð 1000 Da, with a scan time of 1 s. Reverse phase HPLC data was obtained on an Agilent 1200 
series HPLC using a Machery-Nagel Nucleodur C18 column. Analysis was performed using a 
gradient method, eluting with 5 Ð 80% MeCN/H2O over 50 minutes at a flow rate of 1 mL/min. 
Samples for HPLC analysis were prepared through the removal of 30 µL of the reaction mixture in 
which 100 µL of EDTA solution (10 mg/mL) was added. The product was extracted with 100 µL of 
DCM. The organics were concentrated, and the product was dissolved in MeOH (1 mL). To 110 µL of 
this solution was added 5 µL of 2-bromopyrimidine solution (10 mg/mL in MeOH) for HPLC 
analysis. Note: Due to the high heteroatom count in specific products, 13C NMR analysis was not 
possible due to issues with relaxation. 
General Procedures. General Procedure A for the formation of 3a-j (Scheme 3). To a solution of 5,6-
dimethyl-1-((triisopropylsilyl)ethynyl)-1H-benzo[d]imidazole (45 mg, 0.14 mmol, 1 equiv), (but-3-yn-
1-yloxy)benzene (20 mg, 0.14 mmol, 1 equiv) and azide 6a-j (0.14 mmol, 1 equiv) at rt in MeCN (1 
mL) was added TBAF (49 µL, 0.15 mmol, 1.1 equiv) followed by Cu(OAc)2 (1 mg, 0.007 mmol, 0.05 
equiv). The reaction was stirred for 16 h, after which EtOAc (10 mL) was added. The mixture was 
washed with EDTA (10 mg/mL, 10 mL) and brine (2 x 10 mL), dried over Na2SO4, and concentrated 
under vacuum. The resulting residue was purified by flash chromatography (silica gel) to provide the 
desired compound. 
General Procedure B for the formation of 5a-j (Scheme 3). To a solution of 5,6-dimethyl-1-
((triisopropylsilyl)ethynyl)-1H-benzo[d]imidazole (45 mg, 0.14 mmol, 1 equiv), (but-3-yn-1-
yloxy)benzene (20 mg, 0.14 mmol, 1 equiv) and azide  5a-j (0.14 mmol, 1 equiv) at rt in DMSO/H2O 
(1/1, 1 mL) was added AMTC (3 mg, 0.014 mmol, 0.1 equiv) followed by Cu(OAc)2 (1 mg, 0.007 
mmol, 0.05 equiv) and NaAsc (3 mg, 0.014 mmol, 0.1 equiv). The reaction was stirred for 16 h, after 
which EtOAc (10 mL) was added. The mixture was washed with EDTA (10 mg/mL, 10 mL) and brine 
(2 x 10 mL), dried over Na2SO4, and concentrated under vacuum. The resulting residue was purified 
by flash chromatography (silica gel) to provide the desired compound. 
General Procedure C for the formation of 7a-f (Scheme 4). To a solution of 5,6-dimethyl-1-
((triisopropylsilyl)ethynyl)-1H-benzo[d]imidazole (132 mg, 0.41 mmol, 1 equiv), alkyne 2a-f (0.41 
mmol, 1 equiv) and benzyl azide (53 µL, 0.41 mmol, 1 equiv) at rt in DMSO/H2O (1/1, 1 mL) was 
added AMTC (9 mg, 0.041 mmol, 0.1 equiv) followed by Cu(OAc)2 (3 mg, 0.02 mmol, 0.05 equiv) 
and NaAsc (9 mg, 0.041 mmol, 0.1 equiv). The reaction was stirred for 16 h, after which EtOAc was 
added. The mixture was washed with EDTA (10 mg/mL, 10 mL) and brine (2 x 10 mL), dried over 
Na2SO4, and concentrated under vacuum. The resulting residue was purified by flash chromatography 
(silica gel) to provide the desired compound. 
 
1-(1-Benzyl-1H-1,2,3-triazol-4-yl)-5,6-dimethyl-1H-benzo[d]imidazole (3a). Prepared using General 
Procedure A. White solid (31 mg, 66 %). Purification on silica gel using hexane/EtOAc 3/7. 1H NMR 
(CDCl3, 400 MHz): δ 8.20 (br. s, 1H), 7.67 (s, 1H), 7.58 (br. s, 1H), 7.39Ð7.45 (m, 4H), 7.37Ð7.34 (m, 
2H), 5.62 (s, 2H), 2.37 (s, 6H). 13C NMR (CDCl3, 100 MHz): δ 143.2, 142.4, 140.4, 134.0, 133.6, 
132.2, 131.1, 129.5, 129.3, 128.3, 120.7, 113.5, 111.3, 55.2, 20.7, 20.3. IR νmax (neat): 3086, 2922, 
2854, 1724, 1584, 1495, 1459, 1407, 1284, 1213, 1053, 867, 718 cm-1. HRMS (ESI-TOF) m/z: [M + 
H]+ Calcd for C18H18N5 304.1557; Found 304.1551. 
 
5,6-Dimethyl-1-(1-octyl-1H-1,2,3-triazol-4-yl)-1H-benzo[d]imidazole (3b). Prepared using General 
Procedure A. White solid (88 mg, 98%). Purification on silica gel using hexane/EtOAc 3/7. 1H NMR 
(CDCl3, 500 MHz): δ 8.62 (br. s, 1H), 7.77Ð7-68 (m, 3H), 4.45 (t, J = 7.1 Hz, 2H), 2.40 (s, 3H), 2.38 
(s, 3H), 2.00 (app. quint, J = 6.6 Hz, 2H), 1.40Ð1.26 (m, 10H), 0.87 (t, J = 7.2 Hz, 3H). 13C NMR 
(CDCl3, 100 MHz): δ 133.9, 132.0, 113.8, 51.5, 31.8, 30.4, 29.8, 29.2, 29.1, 26.6, 22.7, 20.7, 20.4, 
14.2. IR νmax (neat): 3135, 2924, 2857, 1740, 1597, 1500, 1470, 1383, 1292, 1206, 1156, 1091, 1053, 




Prepared using General Procedure A. White solid (95 mg, 99%). Purification on silica gel using 
hexane/EtOAc 3/7. 1H NMR (CDCl3, 400 MHz): δ 8.22 (br. s, 1H), 7.82 (s, 1H), 7.60 (s, 1H), 7.47 (s, 
1H), 2.39 (s, 3H), 2.38 (s, 3H), 2.33 (br. s, 9H), 1.83 (br. s, 6H). 13C NMR (CDCl3, 100 MHz): δ 
142.4, 142.1, 140.7, 133.5, 132.1, 131.4, 120.7, 111.4, 110.6, 61.0, 43.1, 35.9, 29.8, 29.6, 20.7, 
20.4.IR νmax (neat): 3080, 2917, 2852, 1725, 1586, 1495, 1467, 1448, 1281, 1216, 1149, 1019, 948, 
861, 844 cm-1. HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C21H26N5 348.2183; Found 348.2179. 
 
(S)-5,6-Dimethyl-1-(1-(1-phenylethyl)-1H-1,2,3-triazol-4-yl)-1H-benzo[d]imidazole (3d). Prepared 
using General Procedure A. White solid (46 mg, 95%). Purification on silica gel using hexane/EtOAc 
3/7. 1H NMR (CDCl3, 400 MHz): δ 8.20 (br. s, 1H), 7.63 (s, 1H), 7.59 (br. s, 1H), 7.45Ð7-35 (m, 6H), 
5.88 (q, J = 7.0 Hz, 1H), 2.37 (s, 6H), 2.09 (d, J = 7.1 Hz, 3H). 13C NMR (CDCl3, 100 MHz): δ 139.3, 
133.6, 132.3, 129.4, 126.7, 120.7, 112.6, 111.5, 61.5, 29.8, 21.3, 20.7, 20.4. 4 signals not 
observed/coincident. IR νmax (neat): 3110, 2926, 2857, 1724, 1590, 1498, 1459, 1383, 1286, 1212, 
1143, 910, 731 cm-1. HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C19H20N5 318.1713; Found 318.1704. 
 
(S)-2-((tert-Butoxycarbonyl)amino)-6-(4-(5,6-dimethyl-1H-benzo[d]imidazol-1-yl)-1H-1,2,3-triazol-1-
yl)hexanoic acid (3e). Prepared using General Procedure A. Yellow solid (56 mg, 94%). Purification 
on silica gel using DCM/MeOH 9/1 + 0.01% AcOH. 1H NMR (CDCl3, 400 MHz): δ 9.80 (br. s, 1H), 
8.79 (s, 1H), 7.91 (s, 1H), 7.71 (s, 1H), 4.60 (br. s, 2H), 4.08 (br. s, 1H), 2.48 (s, 6H), 2.08 (br. s, 2H), 
1.89 (br. s, 1H), 1.74 (br. s, 1H), 1.51 (br. s, 2H), 1.41 (s, 9H). 13C NMR (CDCl3, 100 MHz): δ 175.9, 
158.1, 141.0, 139.2, 138.9, 119.9, 116.0, 114.8, 80.4, 54.6, 52.4, 32.2, 30.6, 28.7, 23.9, 20.7, 20.5. 2 
signals not observed/coincident. IR νmax (neat): 3382, 3127, 2974, 2867, 2485, 2233, 2071, 1686, 
1591, 1422, 1392, 1368, 1247, 1165, 1119, 1052, 974 cm-1. HRMS (ESI-TOF) m/z: [M + H]+ Calcd 
for C22H31N6O4 443.2401; Found 443.2389. 
 
5,6-Dimethyl-1-(1-(pyridin-2-ylmethyl)-1H-1,2,3-triazol-4-yl)-1H-benzo[d]imidazole (3f). Prepared 
using General Procedure A. Yellow oil (83 mg, 99%). Purification on silica gel using hexane/EtOAc 
3/7. 1H NMR (CDCl3, 500 MHz): δ 8.61 (d, J = 4.5 Hz, 1H), 8.24 (s, 1H), 8.03 (s, 1H), 7.72 (dt, J = 
7.7, 1.7 Hz, 1H), 7.57 (s, 1H), 7.45 (s, 1H), 7.33 (d, J = 7.7 Hz, 1H), 7.29 (m, 1H), 5.72 (s, 2H), 2.36 
(s, 6H). 13C NMR (CDCl3, 100 MHz): δ 153.6, 150.1, 143.0, 142.3, 140.4, 137.6, 133.6, 133.5, 133.4, 
132.3, 132.2, 132.1, 131.0, 123.8, 122.8, 120.6, 114.3, 111.3. IR νmax (neat): 3105, 2960, 2917, 2852, 




nitrobenzo[c][1,2,5]oxadiazol-4-amine (3g). Prepared using General Procedure A. Red solid (119 mg, 
95%). Purification on silica gel using hexane/EtOAc 1/9. 1H NMR (CDCl3, 400 MHz): δ 8.48 (m, 2H), 
7.63 (s, 1H), 7.49 (br. s, 1H), 6.38 (d, J = 9.3 Hz, 1H), 4.98 (t, J = 4.5 Hz, 2H), 3.45Ð3.42 (m, 2H), 
2.39 (d, J = 4.7 Hz, 6H), 2.03 (s, 3H). 1 signal not observed/coincident. IR νmax (neat): 3599, 3108, 
3082, 2917, 2852, 1613, 1597, 1550, 1424, 1288, 1216, 1149, 1087, 1002, 918, 732 cm-1. HRMS 
(ESI-TOF) m/z: [M + H]+ Calcd for C20H20N9O3 434.1684; Found 434.1613. 
 
N-(3-(4-(5,6-Dimethyl-1H-benzo[d]imidazol-1-yl)-1H-1,2,3-triazol-1-yl)propyl)-5-
(dimethylamino)naphthalene-1-sulfonamide (3h). Prepared using General Procedure A. Yellow solid 
(43 mg, 92%). Purification on silica gel using DCM/MeOH 9/1. 1H NMR (CDCl3, 500 MHz): δ 8.52 
(d, J = 8.6 Hz, 1H), 8.27 (d, J = 8.6 Hz, 1H), 8.24 (s, 1H), 8.21 (d, J = 8.6 Hz, 1H), 7.80 (s, 1H), 7.61 
(s, 1H), 7.55 (t, J = 7.6 Hz, 1H), 7.50Ð7.46 (m, 2H), 7.16 (d, J = 7.6 Hz, 1H), 5.38 (t, J = 6.5 Hz, 1H), 
4.54 (t, J = 5.5 Hz, 2H), 2.94 (q, J = 6.2 Hz, 2H), 2.86 (s, 6H), 2.39 (s, 6H), 2.15 (m, 2H). 13C NMR 
(CDCl3, 100 MHz): δ 152.4, 142.6, 142.4, 140.5, 134.2, 133.8, 132.4, 131.0, 130.1, 129.9, 129.6, 
128.9, 123.4, 120.7, 118.3, 115.5, 114.7, 111.4, 47.7, 45.5, 39.9, 30.2, 20.7, 20.4. IR νmax (neat): 3127, 
2924, 2857, 2794, 1750, 1597, 1457, 1396, 1325, 1312, 1234, 1146, 1092, 1042, 951, 789 cm-1. 
HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C26H30N7O2S 504.2176; Found 504.2153. 
 
1-(3',6'-Dihydroxy-3-oxo-3H-spiro[isobenzofuran-1,9'-xanthen]-5-yl)-3-(3-(4-(5,6-dimethyl-1H-
benzo[d]imidazol-1-yl)-1H-1,2,3-triazol-1-yl)propyl)thiourea (3i). Prepared using General Procedure 
A. Red solid (66 mg, 85%). Purification on silica gel using DCM/MeOH 9/1). 1H NMR (CDCl3, 400 
MHz): δ 9.32 (br. s, 1H), 9.00 (s, 1H), 8.45 (s, 1H), 7.86 (d, J = 8.0 Hz, 1H), 7.82 (s, 1H), 7.65Ð7.62 
(m, 2H), 7.16 (d, J = 8.3 Hz, 1H), 6.72Ð6.68 (m, 2H), 6.60Ð6.56 (m, 3H), 4.66 (t, J = 6.9 Hz, 2H), 3.51 
(s, 2H), 3.16 (s, 2H), 2.40 (s, 3H), 2.38 (s, 3H).IR νmax (neat): 2924, 2113, 1716, 1593, 1541, 1457, 
1381, 1303, 1245, 1210, 854 cm-1. HRMS (ESI-TOF) m/z: [M Ð H]Ð Calcd for C35H28N7O5S 658.1878; 




yl)pentanamide (3j). Prepared using General Procedure A. White solid (24 mg, 87%). Purification on 
silica gel using DCM/MeOH 9/1. 1H NMR (CDCl3, 400 MHz): δ 8.52 (s, 2H), 7.63 (br. s, 1H), 7.55 
(br. s, 1H), 4.71 (t, J = 5.2 Hz, 2H), 4.45 (dd, J = 7.8, 4.9 Hz, 1H), 4.25 (dd, J = 7.9, 4.5 Hz, 1H), 3.99 
(t, J = 4.9 Hz, 2H), 3.69Ð3.66 (m, 2H), 3.64Ð3.62 (m, 2H), 3.58Ð3.55 (m, 2H), 3.49Ð3.47 (m, 2H), 
3.38 (t, J = 5.4 Hz, 2H), 3.24 (t, J = 5.4 Hz, 2H), 3.17Ð3.12 (m, 1H), 2.88 (dd, J = 12.8, 5.0 Hz, 1H), 
2.68 (d, J = 12.7 Hz, 1H), 2.41 (s, 3H), 2.40 (s, 3H), 2.17Ð2.13 (m, 2H), 1.73Ð1.50 (m, 4H), 1.42Ð1.34 
(m, 2H). 13C NMR (CDCl3, 100 MHz): δ 176.0, 166.1, 135.2, 133.9, 120.6, 118.2, 112.9, 71.5, 71.4, 
71.1, 70.5, 63.3, 61.6, 57.0, 52.3, 41.0, 40.2, 36.7, 29.7, 29.4, 26.8, 20.7, 20.3. IR νmax (neat): 3375, 
3124, 2922, 2867, 2470, 2068, 1690, 1645, 1591, 1454, 1098, 1055 cm-1. HRMS (ESI-TOF) m/z: [M + 
H]+ Calcd for C28H43N8O5S 615.3072; Found 615.3149. 
 
1-Benzyl-4-(2-phenoxyethyl)-1H-1,2,3-triazole (5a). Prepared using General Procedure B. White solid 
(81 mg, quant). Purification on silica gel using hexane/EtOAc 3/7. 1H NMR (CDCl3, 400 MHz): δ 
7.40Ð7.34 (m, 4H), 7.29-7.26 (m, 2H), 7.25Ð7.24 (m, 2H), 6.94 (tt, J = 7.4, 1.1 Hz), 6.89Ð6.85 (m, 
2H), 5.50 (s, 2H), 4.23 (t, J = 6.5 Hz, 2H), 3.19 (t, J = 6.5 Hz, 2H). 13C NMR (CDCl3, 100 MHz): δ 
158.8, 135.0, 129.6, 129.2, 128.8, 128.1, 122.0, 121.1, 114.7, 66.8, 54.2, 26.4. IR νmax (neat): 3120, 
3071, 3038, 2958, 2935, 1604, 1590, 1496, 1459, 1251, 1219, 1176, 1059, 1042, 890, 828, 789, 752, 
720 cm-1. HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C17H17N3ONa 302.1264; Found 302.1256. 
 
1-Octyl-4-(2-phenoxyethyl)-1H-1,2,3-triazole (5b). Prepared using General Procedure B. White solid 
(78 mg, 94%). Purification on silica gel using hexane/EtOAc 3/7.  1H NMR (CDCl3, 400 MHz): δ 7.41 
(s, 1H), 7.29Ð7.25 (m, 2H), 6.96Ð6.89 (m, 3H), 4.30 (t, J = 7.2 Hz, 2H), 4.24 (t, J = 6.5 Hz, 2H), 3.21 
(t, J = 6.5 Hz, 2H), 1.87 (app. quint, J = 7.1 Hz, 2H), 1.30Ð1.25 (m, 10H), 0.87 (t, J = 6.6 Hz, 3H). 13C 
NMR (CDCl3, 100 MHz): δ 158.7, 144.6, 129.6, 121.7, 121.0, 114.6, 66.8, 50.3, 31.8, 30.4, 29.1, 29.0, 
26.6, 26.3, 22.7, 14.1.  IR νmax (neat): 3142, 2956, 2922, 2852, 1604, 1591, 1500, 1487, 1388, 1247, 
1217, 1176, 1057, 1035, 886, 817, 756, 694 cm-1. HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for 
C18H27N3ONa 324.2046; Found 324.2035. 
 
1-((3s,5s,7s)-Adamantan-1-yl)-4-(2-phenoxyethyl)-1H-1,2,3-triazole (5c). Prepared using General 
Procedure B. White solid (81 mg, quant). Purification on silica gel using hexane/EtOAc 3/7. 1H NMR 
(CDCl3, 400 MHz): δ 7.49 (s, 1H), 7.30Ð7.28 (m, 2H), 7.00Ð6.90 (m, 3H), 4.25 (t, J = 6.6 Hz, 2H), 
3.22 (t, J = 6.6 Hz, 2H), 2.25Ð2.23 (m, 9H), 1.82Ð1.75 (m, 6H). 13C NMR (CDCl3, 100 MHz): δ 158.9, 
143.7, 129.6, 121.0, 118.2, 114.7, 67.1, 59.4, 43.1, 36.1, 29.6, 26.5. IR νmax (neat): 2909, 2857, 1599, 
1590, 1556, 1500, 1476, 1457, 1420, 1348, 1292, 1243, 1035, 1016, 780, 759, 694 cm-1. HRMS (ESI-
TOF) m/z: [M + Na]+ Calcd for C20H25N3ONa 346.1890; Found 346.1881. 
 
(S)-4-(2-Phenoxyethyl)-1-(1-phenylethyl)-1H-1,2,3-triazole (5d). Prepared using General Procedure B. 
White solid (67 mg, 84%). Purification on silica gel using hexane/EtOAc 3/7). 1H NMR (CDCl3, 400 
MHz): δ 7.38Ð7.32 (m, 8H), 6.94 (tt, J = 7.4, 1.1 Hz, 1H), 6.88Ð6.85 (m, 2H), 5.78 (q, J = 7.2 Hz, 1H), 
4.23 (t, J = 6.5 Hz, 2H), 3.19 (t, J = 6.5 Hz, 2H), 1.97 (d, J = 7.1 Hz, 3H). 13C NMR (CDCl3, 100 
MHz): δ 158.7, 144.6, 140.2, 129.6, 129.1, 128.5, 126.6, 121.0, 120.8, 114.7, 66.8, 60.2, 25.4, 21.4.  
IR νmax (neat): 3170, 3066, 3030, 3045, 2941, 2924, 2870, 1604, 1588, 1498, 1463, 1387, 1366, 1305, 
1251, 1038, 811, 756, 733, 705, 694 cm-1. HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C18H19N3ONa 
316.1420; Found 316.1410. 
 
(S)-2-((tert-Butoxycarbonyl)amino)-6-(4-(2-phenoxyethyl)-1H-1,2,3-triazol-1-yl)hexanoic acid (5e). 
Prepared using General Procedure B. White solid (46 mg, 82%). Purification on silica gel using 
DCM/MeOH 9/1, 0.1% AcOH. 1H NMR (MeOD, 500 MHz): δ 7.83 (br. s, 1H), 7.24 (t, J = 7.8 Hz, 
2H), 6.92Ð6.89 (m, 3H), 4.37 (t, J = 7.1 Hz, 2H), 4.22 (t, J = 6.5 Hz, 2H), 4.08Ð4.05 (m, 1H), 3.15 (t, J 
= 6.4 Hz, 2H), 1.94Ð1.89 (m, 2H), 1.87Ð1.80 (m, 2H), 1.70Ð1.55 (m, 2H), 1.42 (s, 9H). 13C NMR 
(MeOD, 100 MHz): δ 176.0, 158.1, 130.5, 121.9, 115.6, 80.5, 67.7, 54.6, 52.2, 51.1, 32.3, 32.2, 29.4, 
28.7, 26.9, 23.9.IR νmax (neat): 3398, 2952, 2922, 2868, 2482, 2242, 2071, 1688, 1600, 1368, 1167, 
1119, 974 cm-1. HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C21H30N4O5Na 441.2108; Found 
441.2102. 
 
2-((4-(2-Phenoxyethyl)-1H-1,2,3-triazol-1-yl)methyl)pyridine (5f). Prepared using General Procedure 
B. White solid (60 mg, 79%). Purification on silica gel using hexane/EtOAc 3/7. 1H NMR (CDCl3, 
400 MHz): δ 8.60 (s, 1H), 7.67 (tt, J = 7.8, 1.8 Hz, 1H), 7.60 (s, 1H), 7.29Ð7.24 (m, 4H), 7.15 (d, J = 
7.7 Hz, 1H), 6.93 (tt, J = 7.3, 1.2 Hz, 1H), 6.88 (m, 1H), 5.63 (s, 2H), 4.25 (t, J = 6.5 Hz, 2H), 3.22 (t, 
J = 6.5 Hz, 2H). 13C NMR (CDCl3, 100 MHz): δ 158.8, 137.5, 129.6, 123.5, 121.1, 114.7, 66.8, 55.7, 
26.4. 3 signals not observed/coincident. IR νmax (neat): 3142, 2932, 1601, 1590, 1496, 1474, 1441, 
1295, 1241, 1052, 1022, 1035, 998, 752, 692 cm-1. HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for 
C16H16N4ONa 303.1216; Found 303.1214. 
 
N-Methyl-7-nitro-N-(2-(4-(2-phenoxyethyl)-1H-1,2,3-triazol-1-yl)ethyl)benzo[c][1,2,5]oxadiazol-4-
amine (5g). Prepared using General Procedure B.  Yellow solid (118 mg, 85%). Purification on silica 
gel using hexane/EtOAc 1/9. 1H NMR (CDCl3, 500 MHz): δ 8.37 (d, J = 9.0 Hz, 1H), 7.86 (br. s, 1H), 
7.24 (t, J = 7.7 Hz, 2H), 6.92 (t, J = 7.3 Hz, 1H), 6.84 (d, J = 8.0 Hz, 2H), 6.20 (d, J = 8.9 Hz, 1H), 
4.68 (m, 2H), 4.01 (t, J = 6.0 Hz, 2H), 3.03 (t, J = 6.0 Hz, 2H), 1.34Ð1.29 (m, 5H). IR νmax (neat): 
3142, 1617, 1556, 1483, 1429, 1303, 1281, 1095, 1035, 1000, 801, 756, 682 cm-1. HRMS (ESI-TOF) 
m/z: [M + Na]+ Calcd for C19H19N7O4Na 432.1391; Found 432.1376. 
13C NMR could not be obtained 
due to relaxation issues. 
 
5-(Dimethylamino)-N-(3-(4-(2-phenoxyethyl)-1H-1,2,3-triazol-1-yl)propyl)naphthalene-1-sulfonamide 
(5h). Prepared using General Procedure B. Yellow solid (38 mg, 87%). Purification on silica gel using 
DCM/MeOH 9/1. 1H NMR (CDCl3, 400 MHz): δ 8.53 (dt, J = 8.5, 0.9 Hz, 1H), 8.27 (dt, J = 8.5, 0.9 
Hz, 1H), 8.18 (dd, J = 7.3, 1.2 Hz, 1H), 7.55 (dd, J = 8.6, 7.6 Hz, 1H), 7.47 (dd, J = 8.5, 7.2 Hz, 1H), 
7.33 (s, 1H), 7.28Ð7.24 (m, 2H), 7.16 (d, J = 7.6 Hz, 1H), 6.95Ð6.88 (m, 3H), 5.41 (t, J = 6.5 Hz, 1H), 
4.32 (t, J = 6.6 Hz, 2H), 4.20 (t, J = 6.3 Hz, 2H), 3.15 (t, J = 6.3 Hz, 2H), 2.87 (s, 6H), 2.01 (m, 
4H).13C NMR (CDCl3, 100 MHz): δ 158.7, 152.2, 134.5, 130.8, 130.0, 129.8, 129.6, 128.7, 123.3, 
121.0, 118.6, 115.4, 114.7, 66.7, 46.9, 45.5, 40.1, 32.0, 30.4, 29.8, 26.2, 14.3. IR νmax (neat): 3293, 
3142, 2935, 2870, 2790, 1603, 1590, 1577, 1500, 1457, 1409, 1396, 1314, 1236, 1145, 1038, 947, 




1,2,3-triazol-1-yl)propyl)thiourea (5i). Prepared using General Procedure B. Red solid (68 mg, 91%). 
Purification on silica gel using DCM/MeOH 9/1. 1H NMR (CDCl3, 500 MHz): δ 8.72 (br. s, 1H), 8.38 
(s, 1H), 8.06 (s, 1H), 7.83 (d, J = 7.7 Hz, 1H), 7.27 (t, J = 7.1 Hz, 2H), 7.17 (d, J = 7.1 Hz, 1H), 6.95 
(m, 2H), 6.71 (s, 3H), 6.58 (q, J = 8.2 Hz, 3H), 4.45 (t, J = 6.4 Hz, 2H), 4.22 (t, J = 6.6 Hz, 4H), 3.51 
(m, 2H), 3.09 (t, J = 6.4 Hz, 2H). IR νmax (neat): 2928, 1638, 1591, 1541, 1457, 1381, 1295, 1238, 
1210, 1176, 1120, 852 cm-1. HRMS (ESI-TOF) m/z: [M - H]- Calcd for C34H28N5O6S 634.1766, found 
618.2001 [M - OH]. 13C NMR could not be obtained due to relaxation issues. 
 
5-((3aS,4S,6aR)-2-Oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)-N-(2-(2-(2-(2-(4-(2-phenoxyethyl)-
1H-1,2,3-triazol-1-yl)ethoxy)ethoxy)ethoxy)ethyl)pentanamide (5j). Prepared using General Procedure 
B. White solid (32 mg, 88%). Purification on silica gel using DCM/MeOH 9/1. 1H NMR (CDCl3, 400 
MHz,): δ 7.96 (br. s, 1H), 7.25 (t, J = 7.7 Hz, 2H), 6.92 (d, J = 7.2 Hz, 3H), 4.56 (t, J = 4.6 Hz, 2H), 
4.47 (dd, J = 7.6, 5.6 Hz, 1H), 4.28 (dd, J = 7.9, 4.3 Hz, 1H), 4.24 (t, J = 5.1 Hz, 2H), 3.88 (t, J = 4.7 
Hz, 2H), 3.63Ð3.54 (m, 8H), 3.50 (t, J = 5.1 Hz, 2H), 3.37Ð3.33 (m, 2H), 3.20Ð3.17 (m, 3H), 2.90 (dd, 
J = 12.5, 4.8 Hz, 1H), 2.70 (d, J = 12.7 Hz, 1H), 2.19 (t, J = 7.4 Hz, 2H), 1.75Ð1.54 (m, 4H), 1.41 
(app. quint, J = 7.5 Hz, 2H). 13C NMR (CDCl3, 100 MHz): δ 176.1, 166.1, 160.2, 130.5, 121.9, 115.7, 
71.6, 71.5, 71.4, 71.2, 10.6, 70.4, 67.8, 63.4, 61.6, 57.0, 51.5, 41.1, 40.3, 36.7, 29.7, 29.5, 27.0, 26.8. 1 
signal not observed/coincident. IR νmax (neat): 3274, 3071, 2917, 2861, 1695, 1679, 1643, 1545, 1474, 




29 Prepared using General Procedure C. White 
solid (99 mg, 99%). Purification on silica gel using hexane/EtOAc 7/3. 1H NMR (CDCl3, 400 MHz): δ 
7.82 (s, 1H), 7.36Ð7.33 (m, 3H), 7.28Ð7.26 (m, 2H), 5.48 (s, 2H), 4.56Ð4.52 (m, 2H), 4.25Ð4.21 (m, 
2H). 13C NMR (CDCl3, 100 MHz): δ 154.9, 144.1, 134.4, 129.2, 129.0, 128.2, 111.9, 63.4, 54.9, 43.7. 
 
(1-Benzyl-1H-1,2,3-triazol-4-yl)(pyrrolidin-1-yl)methanone (7c). Prepared using General Procedure C. 
White solid (105 mg, quant). Purification on silica gel using hexane/EtOAc 7/3. 1H NMR (CDCl3, 400 
MHz): δ 8.02 (s, 1H), 7.36Ð7.34 (m, 3H), 7.28Ð7.26 (m, 2H), 5.52 (s, 2H), 4.09 (t, J = 6.7 Hz, 2H), 
3.62 (t, J = 6.9 Hz, 2H), 1.97 (app. quint, J = 7.1 Hz, 2H), 1.88 (app. quint, J = 7.1 Hz, 2H). 13C NMR 
(CDCl3, 100 MHz): δ 159.5, 145.5, 134.1, 129.3, 129.0, 128.3, 127.6, 54.3, 48.7, 47.0, 26.6, 23.8. IR 
νmax (neat): 3298, 3099, 2939, 2861, 2190, 1600, 1543, 1498, 1424, 1342, 1279, 1229, 1048 cm
-1. 
HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C14H16N4ONa 279.1216; Found 279.1206. 
 
1-Benzyl-4-(phenoxymethyl)-1H-1,2,3-triazole (7d).
30 Prepared using General Procedure C. White 
solid (106 mg, 97%). Purification on silica gel using hexane/EtOAc 9/1. 1H NMR (CDCl3, 400 MHz): 
δ 7.52 (s, 1H), 7.37Ð7.35 (m, 3H), 7.29Ð7.25 (m, 4H), 6.97Ð6.95 (m, 3H), 5.52 (s, 2H), 5.18 (s, 2H). 




31 Prepared using General Procedure C. White solid (94 
mg, 92%). Purification on silica gel using hexane/EtOAc 9/1. 1H NMR (CDCl3, 400 MHz): δ 7.70 (s, 
1H), 7.68 (s, 1H), 7.62 (s, 1H), 7.39Ð7.36 (m, 3H), 7.32Ð7.31 (m, 1H), 7.30Ð7.29 (m, 1H), 7.21 (s, 
1H), 7.19 (s, 1H), 5.56 (s, 2H), 2.36 (s, 3H). 13C NMR (CDCl3, 100 MHz): δ 148.4, 138.1, 134.9, 
129.6, 129.3, 128.9, 128.2, 127.9, 125.7, 119.3, 54.3, 21.4. 
 
1-Benzyl-4-propyl-1H-1,2,3-triazole (7f).
32 Prepared using General Procedure C. White solid (70 mg, 
85%). Purification on silica gel using hexane. 1H NMR (CDCl3, 400 MHz): δ 7.36Ð7.31 (m, 3H), 
7.24Ð7.21 (m, 2H), 7.18 (s, 1H), 5.47 (s, 2H), 2.64 (t, J = 7.4 Hz, 2H), 1.64 (sextet, J = 7.4 Hz, 2H), 
0.9 (t, J = 7.4 Hz, 3H). 13C NMR (CDCl3, 100 MHz): δ 148.8, 135.1, 129.1, 128.6, 128.0, 120.7, 54.0, 
27.8, 22.7, 13.8. 
 
5-(1-Benzyl-1H-1,2,3-triazol-4-yl)-N-(1-((triisopropylsilyl)ethynyl)-1H-benzo[d]imidazol-6-
yl)pentanamide (9a). To a solution of N-(1-((triisopropylsilyl)ethynyl)-1H-benzo[d]imidazol-6-
yl)hept-6-ynamide (50 mg, 0.119 mmol, 1 equiv.) in MeOH/H2O (1/1, 2 mL) was added benzyl azide 
(15 µL, 0.119 mmol, 1 equiv.), AMTC (3 mg, 0.012 mmol, 0.1 equiv.), Cu(OAc)2 (1 mg, 0.006 mmol, 
0.05 equiv.), and NaAsc (3 mg, 0.012 mmol, 0.1 equiv.). The reaction was stirred at rt for 16 h, after 
which DCM (10 mL) was added. The mixture was washed with aq. EDTA (10 mg/mL, 10 mL), brine 
(2 x 10 mL), dried over Na2SO4, and concentrated under reduced pressure. The resulting residue was 
purified by flash chromatography (silica gel, hexane/ EtOAc 3/7) to provide the desired product as a 
white solid (62 mg, 98%). 1H NMR (CDCl3, 400 MHz,): δ 8.75 (s, 1H), 8.24 (s, 1H), 8.05 (br. s, 1H), 
7.64 (br. s, 1H), 7.35Ð7.30 (m, 4H), 7.23Ð7.21 (m, 3H), 5.45 (s, 2H), 2.71 (t, J = 6.9 Hz, 2H), 2.43 (t, J 
= 6.9 Hz, 2H), 1.79Ð1.70 (m, 4H), 1.14 (s, 21H). 13C NMR (CDCl3, 100 MHz): δ 171.8, 136.3, 134.8, 
129.2, 128.8, 128.1, 120.6, 117.0, 102.6, 73.5, 54.2, 37.1, 29.8, 28.6, 25.1, 25.0, 18.7, 11.3. 5 signals 
not observed/coincident. IR νmax (neat): 3251, 2937, 2859, 2184, 1664, 1602, 1548, 1498, 1441, 1216, 
909, 883, 730 cm-1. HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C32H42N6OSiNa 577.3082; Found 
577.3122. 
 
N-(1-(1-Cyclohexyl-1H-1,2,3-triazol-4-yl)-1H-benzo[d]imidazol-6-yl)hept-6-ynamide (9b). To a 
solution of N-(1-((triisopropylsilyl)ethynyl)-1H-benzo[d]imidazol-6-yl)hept-6-ynamide (50 mg, 0.12 
mmol, 1 equiv.) in MeCN (1 mL) was added cyclohexylazide (15 mg, 0.12 mmol, 1 equiv.), TBAF 
(43 µL, 0.13 mmol, 1.1 equiv.), and Cu(OAc)2 (1 mg, 0.006 mmol, 0.05 equiv.). The reaction was 
stirred at rt for 16 h, after which DCM (10 mL) was added. The mixture was washed with aq. EDTA 
(10 mg/mL, 10 mL), brine (2 x 10 mL), dried over Na2SO4, and concentrated under reduced pressure. 
The resulting residue was purified by flash chromatography (silica gel, 7/3 EtOAc/hexane) to provide 
the desired product as a white solid (45 mg, 96%). 1H NMR (CDCl3, 400 MHz,): δ 8.40 (br. s, 1H), 
8.34 (s, 1H), 8.08 (br. s, 1H), 7.85 (s, 1H), 7.68 (br. s, 1H), 7.07 (d, J = 5.9 Hz, 1H), 4.48 (tt, J = 11.8, 
3.6 Hz, 1H), 2.41 (t, J = 7.4 Hz, 2H), 2.27 (d, J = 12.4 Hz, 2H), 2.21 (dt, J = 7.2, 2.1 Hz, 2H), 1.96 (m, 
3H), 1.89Ð1.82 (m, 4H), 1.59 (app. quint, J = 7.8 Hz, 2H), 1.52Ð1.41 (m, 2H), 1.32 (dt, J = 12.8, 2.7 
Hz, 2H). 13C NMR (CDCl3, 100 MHz): δ 171.5, 141.7, 135.1, 120.7, 116.1, 112.4, 102.7, 84.1, 68.9, 
61.4, 37.2, 33.5, 28.0, 25.2, 25.1, 24.8, 18.3. 3 signals not observed/coincident. IR νmax (neat): 3289, 
3259, 3123, 3080, 2930, 2855, 1673, 1604, 1587, 1550, 1487, 1442, 1299, 1240, 911, 803, 730 cm-1. 
HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C22H26N6ONa 413.2060; Found 413.2049. 
 
5-(1-Cyclohexyl-1H-1,2,3-triazol-4-yl)-N-(1-((triisopropylsilyl)ethynyl)-1H-benzo[d]imidazol-6-
yl)pentanamide (10a). To a solution of N-(1-((triisopropylsilyl)ethynyl)-1H-benzo[d]imidazol-6-
yl)hept-6-ynamide (50 mg, 0.119 mmol, 1 equiv.) in MeOH/H2O (1/1, 2 mL) was added 
cyclohexylazide (15 mg, 0.12 mmol, 1 equiv.), AMTC (3 mg, 0.012 mmol, 0.1 equiv.), Cu(OAc)2 (1 
mg, 0.006 mmol, 0.05 equiv.), and NaAsc (3 mg, 0.012 mmol, 0.1 equiv.). The reaction was stirred at 
rt for 24 h, after which DCM (10 mL) was added. The mixture was washed with aq. EDTA (10 
mg/mL, 10 mL), brine (2 x 10 mL), dried over Na2SO4, and concentrated under reduced pressure. The 
resulting residue was purified by flash chromatography (silica gel, hexane/ EtOAc 3/7) to provide the 
desired product as a white solid (42 mg, 63%). 1H NMR (CDCl3, 400 MHz,): δ 8.51 (br. s, 1H), 8.20 
(d, J = 1.6 Hz, 1H), 8.01 (s, 1H), 7.66 (d, J = 8.7 Hz, 1H), 7.32 (dd, J = 8.6, 1.7 Hz, 1H), 7.29 (s, 1H), 
4.38 (tt, J = 11.8, 3.8 Hz, 1H), 2.75 (t, J = 6.9 Hz, 2H), 2.45 (t, J = 6.7 Hz, 2H), 2.18Ð2.15 (m, 2H), 
1.92Ð1.87 (m, 2H), 1.83Ð1.65 (m, 6H), 1.48Ð1.37 (m, 2H), 1.27Ð1.21 (m, 2H), 1.16Ð1.14 (m, 21H). 
13C NMR (CDCl3, 100 MHz): δ 171.8, 147.2, 143.8, 138.2, 136.2, 135.0, 120.8, 118.7, 117.0, 102.6, 
90.1, 73.4, 60.1, 37.2, 33.7, 28.6, 25.3, 25.3, 25.1, 25.0, 18.8, 11.3. 9 signals not observed/coincident. 
IR νmax (neat): 3296, 3132, 3075, 2935, 2859, 2184, 1686, 1664, 1602, 1547, 1500, 1483, 1441, 1376, 
1284, 1216, 1071? 998, 885, 680 cm-1. HRMS (ESI-TOF): m/z: [M + Na]+ Calcd for C31H46N6OSiNa 
569.3395; Found 569.3382. 
 
N-(1-(1-Benzyl-1H-1,2,3-triazol-4-yl)-1H-benzo[d]imidazol-6-yl)hept-6-ynamide (10b). To a solution 
of N-(1-((triisopropylsilyl)ethynyl)-1H-benzo[d]imidazol-6-yl)hept-6-ynamide (50 mg, 0.12 mmol, 1 
equiv.) in MeCN (1 mL) was added benzyl azide (15 µL, 0.119 mmol, 1 equiv.), TBAF (43 µL, 0.13 
mmol, 1.1 equiv.), and Cu(OAc)2 (1 mg, 0.006 mmol, 0.05 equiv.). The reaction was stirred at rt for 2 
h, after which DCM (10 mL) was added. The mixture was washed with aq. EDTA (10 mg/mL, 10 
mL), brine (2 x 10 mL), dried over Na2SO4, and concentrated under reduced pressure. The resulting 
residue was purified by flash chromatography (silica gel, 9/1 EtOAc/hexane) to provide the desired 
product as a white solid (47 mg, 98%). 1H NMR (CDCl3, 400 MHz,): δ 8.37 (br. s, 1H), 8.25 (br. s, 
1H), 8.01 (br. s, 1H), 7.88 (s, 1H), 7.68 (d, J = 8.7 Hz, 1H), 7.39Ð7.34 (m, 5H), 7.20 (dd, J = 8.6, 1.7 
Hz, 1H), 5.61 (s, 2H), 3.12Ð3.08 (m, 2H), 2.42 (t, J = 7.3 Hz, 2H), 2.22 (td, J = 7.2, 2.7 Hz, 2H), 1.95 
(t, J = 2.5 Hz, 1H), 1.88Ð1.80 (m 2H). 13C NMR (CDCl3, 100 MHz): δ 171.3, 135.2, 134.1, 129.4, 
129.2, 128.3, 120.6, 116.2, 114.2, 102.5, 84.2, 68.8, 55.2, 37.1, 28.0, 24.7, 19.7, 18.3. 6 signals not 
observed/coincident. IR νmax (neat): 2954, 2961, 2865, 1599, 1589, 1439, 1396, 1080, 1065, 1041, 




yl)pentanamide (11a). Method A: To a solution of 5-(1-benzyl-1H-1,2,3-triazol-4-yl)-N-(1-
((triisopropylsilyl)ethynyl)-1H-benzo[d]imidazol-6-yl)pentanamide (64 mg, 0.12 mmol, 1 equiv.) in 
MeCN (1 mL) was added cyclohexylazide  (15 mg, 0.12 mmol, 1 equiv.), TBAF (43 µL, 0.13 mmol, 
1.1 equiv.) and Cu(OAc)2 (1 mg, 0.006 mmol, 0.05 equiv.). The reaction was stirred at rt for 16 h, 
after which DCM (10 mL) was added. The mixture was washed with aq. EDTA (10 mg/mL, 10 mL), 
brine (2 x 10 mL), dried over Na2SO4 and concentrated under reduced pressure. The resulting residue 
was purified by flash chromatography (silica gel, 9/1 EtOAc/hexane) to provide the desired product as 
a white solid (61 mg, 98%). Method B: To a solution of 5-(1-benzyl-1H-1,2,3-triazol-4-yl)-N-(1-
((triisopropylsilyl)ethynyl)-1H-benzo[d]imidazol-6-yl)pentanamide (20 mg, 0.051 mmol, 1 equiv.) in 
MeOH/H2O (1/1, 2 mL) was added benzyl azide (7 µL, 0.051 mmol, 1 equiv.), AMTC (1 mg, 0.0051 
mmol, 0.1 equiv.), Cu(OAc)2 (0.5 mg, 0.0026 mmol, 0.05 equiv.) and NaAsc (1 mg, 0.0026 mmol, 0.1 
equiv.). The reaction was stirred at rt for 16 h, after which DCM (10 mL) was added. The mixture was 
washed with aq. EDTA (10 mg/mL, 10 mL), brine (2 x 10 mL), dried over Na2SO4 and concentrated 
under reduced pressure. The resulting residue was purified by flash chromatography (silica gel, 9/1 
EtOAc/hexane) to provide the desired product as a white solid (25 mg, 94%). 1H NMR (CDCl3, 400 
MHz,): δ 8.23 (s, 1H), 8.40 (br. s, 1H), 8.38 (s, 1H), 7.92 (s, 1H), 7.68 (d, J = 7.5 Hz, 1H), 7.33Ð7.30 
(m, 4H), 7.23Ð7.20 (m, 3H), 5.45 (s, 2H), 4.47 (tt, J = 11.8, 3.8 Hz, 1H), 2.69 (t, J = 6.5 Hz, 2H), 2.43 
(t, J = 6.7 Hz, 2H), 2.25 (dd, J = 12.7, 2.4 Hz, 2H), 1.95Ð1.89 (m, 2H), 1.84 (dd, J = 12.1, 3.6 Hz, 2H), 
1.79Ð1.70 (m, 6H), 1.47 (tt, J = 12.9, 3.5 Hz, 2H). 13C NMR (CDCl3, 100 MHz): δ 172.0, 135.5, 
134.9, 129.2, 128.8, 128.1, 121.1, 120.6, 116.3, 112.3, 102.4, 61.3, 54.1, 37.1, 33.4, 28.6, 25.3, 26.2, 
25.1, 25.0. 5 signals not observed/coincident. IR νmax (neat): 3257, 3125, 3062, 2922, 2852, 2093, 
1671, 1584, 1547, 1496, 1485, 1446, 1299, 1216, 1050, 816, 799, 729 cm-1. HRMS (ESI-TOF) m/z: 
[M + Na]+ Calcd for C29H33N9ONa 546.2700; Found 546.2660. 
 
N-(1-(1-Benzyl-1H-1,2,3-triazol-4-yl)-1H-benzo[d]imidazol-6-yl)-5-(1-cyclohexyl-1H-1,2,3-triazol-4-
yl)pentanamide (11b). Method A: To a solution of 5-(1-cyclohexyl-1H-1,2,3-triazol-4-yl)-N-(1-
((triisopropylsilyl)ethynyl)-1H-benzo[d]imidazol-6-yl)pentanamide (30 mg, 0.06 mmol, 1 equiv.) in 
MeCN (1 mL) was added benzyl azide  (7 µL, 0.06 mmol, 1 equiv.), TBAF (20 µL, 0.07 mmol, 1.1 
equiv.) and Cu(OAc)2 (0.5 mg, 0.003 mmol, 0.05 equiv.). The reaction was stirred at rt for 2 h, after 
which DCM (10 mL) was added. The mixture was washed with aq. EDTA (10 mg/mL, 10 mL), brine 
(2 x 10 mL), dried over Na2SO4 and concentrated under reduced pressure. The resulting residue was 
purified by flash chromatography (silica gel, 9/1 EtOAc/hexane) to provide the desired product as a 
white solid (30 mg, 95%). Method B: To a solution of N-(1-(1-benzyl-1H-1,2,3-triazol-4-yl)-1H-
benzo[d]imidazol-6-yl)hept-6-ynamide (30 mg, 0.08 mmol, 1 equiv.) in MeOH/H2O (1/1, 2 mL) was 
added cyclohexylazide (10 mg, 0.08 mmol, 1 equiv.), AMTC (1.6 mg, 0.008 mmol, 0.1 equiv.), 
Cu(OAc)2 (0.8 mg, 0.004 mmol, 0.05 equiv.) and NaAsc (3 mg, 0.008 mmol, 0.1 equiv.). The reaction 
was stirred at rt for 24 h, after which DCM (10 mL) was added. The mixture was washed with aq. 
EDTA (10 mg/mL, 10 mL), brine (2 x 10 mL), dried over Na2SO4 and concentrated under reduced 
pressure. The resulting residue was purified by flash chromatography (silica gel, 9/1 EtOAc/hexane) to 
provide the desired product as a yellow solid (30 mg, 71%). 1H NMR (CDCl3, 400 MHz,): δ 8.67 (br. 
s, 1H), 8.10 (br.s, 1H), 7.88 (br. s, 1H), 7.41Ð7.38 (m, 6H), 7.23 (m, 2H), 5.65 (s, 2H), 3.24 (m, 2H), 
2.48 (t, J = 5.8 Hz, 2H), 2.29Ð2.26 (m, 1H), 2.20Ð2.18 (m, 2H), 1.90Ð1.75 (m, 6H), 1.69Ð1.60 (m 4H), 
1.45Ð1.42 (m, 2H). 13C NMR (CDCl3, 100 MHz): δ 129.4, 129.2, 128.3, 124.6, 31.6, 30.3, 29.8, 29.6, 
28.0, 25.3, 24.8, 24.5, 20.0, 13.9. 15 signals not observed/coincident. IR νmax (neat): 3300, 2954, 2928, 
2855, 1736, 1677, 1628, 1600, 1587, 1548, 1496, 1441, 1455, 1379, 1364, 1301, 1234, 864, 821, 725 
cm-1. HRMS (ESI-TOF): m/z: [M + Na]+ Calcd for C29H33N9ONa 546.2700; Found 546.2689. 
2-((4-(p-Tolyl)-1H-1,2,3-triazol-1-yl)methyl)pyridine (12).
33 To a solution of 5,6-dimethyl-1-
((triisopropylsilyl)ethynyl)-1H-benzo[d]imidazole 1 (49 mg, 0.15 mmol, 1 equiv.) and 1-ethynyl-4-
methylbenzene (19 µL, 0.15 mmol, 1 equiv.) in MeCN (0.75 mL) was added 2-(azidomethyl)pyridine 
(20 mg, 0.15 mmol, 1 equiv.), (azidomethyl)benzene (19 µL, 0.15 mmol, 1 equiv.), and Cu(OAc)2 (1.4 
mg, 0.0075 mmol, 0.05 equiv.). The reaction was stirred at rt for 5 h before being filtered through 
celite and concentrated under reduced pressure. The crude mixture was dissolved in MeCN (0.75 mL) 
before adding Cu(OAc)2 (1.4 mg, 0.0075 mmol, 0.05 equiv.) and TBAF (1 M in THF, 22.5 µL, 0.225 
mmol, 1.5 equiv.). The reaction was stirred at rt for a further 16 h, after which EtOAc (10 mL) was 
added. The mixture was washed with aq. EDTA (10 mg/mL, 10 mL), brine (2 x 10 mL), dried over 
Na2SO4, and concentrated under reduced pressure. The resulting residue was purified by flash 
chromatography (silica gel, Et2O/MeOH/NEt3 20/1/1) to provide the desired product as a white solid 
(32 mg, 85%). 1H NMR (CDCl3, 500 MHz): δ 8.61 (br. s, 1H), 7.89 (s, 1H), 7.72 (s, 1H), 7.71 (s, 1H), 
7.68 (td, J = 7.6, 1.4 Hz, 1H), 7.26 (t, J = 5.4 Hz, 1H), 7.22 (t, J = 5.6 Hz, 3H), 5.69 (s, 2H), 2.36 (s, 
3H). 13C NMR (CDCl3, 100 MHz): δ 154.7, 149.8, 148.5, 138.1, 137.5, 129.6, 127.8, 125.7, 123.6, 
122.6, 120.0, 55.8, 21.4. 
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